Enhertu and Klygefa Received European Panel Support
European regulators have recommended new treatment options for adults with HER2-positive breast cancer and generalized myasthenia gravis.
Updated on Sept. 21, 2026 in Cancer
Live Poll
Do you trust pharmaceutical companies to prioritize patient health during the drug approval process?
The European Committee for Medicinal Products for Human Use has recommended two new treatments for regulatory approval. These therapies offer new options for patients with specific forms of breast cancer and generalized myasthenia gravis.
Why it matters
These recommendations provide a pathway for patients to access advanced targeted therapies that have demonstrated clinical benefit in trials. Following these approvals, patients may have new tools for managing disease progression and symptom control.
The Enhertu recommendation is based on the DESTINY-Breast05 trial, which followed patients for three years to measure invasive disease-free survival. Findings showed 92% of Enhertu patients remained disease-free compared to 84% for those treated with T-DM1.
The players
European Committee for Medicinal Products for Human Use
The regulatory body responsible for providing scientific opinions on medicines for the European Union.
Astrazeneca
A global pharmaceutical company that develops treatments for oncology, cardiovascular, and rare diseases.
The details
Enhertu is designed as an adjuvant therapy for patients with HER2-positive breast cancer who have persistent invasive disease following neoadjuvant treatment. Klygefa acts as a dual-binding nanobody C5 inhibitor to manage symptoms in adults with AChR-positive generalized myasthenia gravis. The recommendation for Klygefa is supported by the 26-week PREVAIL study, which demonstrated improvements in patient symptoms relative to a placebo group.
Timeline
The PREVAIL study lasted 26 weeks.
The DESTINY-Breast05 trial monitored patient status over three years.
Health Landscape
These regulatory recommendations follow the established arc of utilizing targeted biologics and nanobody inhibitors for complex chronic conditions. They build upon findings from the DESTINY-Breast05 trial, marking a continued shift toward precision medicine in both oncology and neurology.
These regulatory steps indicate that new options for breast cancer and gMG care are moving closer to clinical availability. You should discuss with your doctor whether these developing treatment pathways align with your current care plan or could be relevant to your future management.
The takeaway
European regulators have moved to clear two significant therapies for patients with complex cancer and autoimmune conditions. Patients should continue to monitor updates regarding final approval and consult their physician about new treatment options emerging from these recent clinical findings.
Further reading
For more on the current standard of care and emerging therapies, visit our Cancer section.
Live Poll
Do you trust pharmaceutical companies to prioritize patient health during the drug approval process?
